TP53 and acute myeloid leukemia: In contrast to idasanutlin all AML cells including the TP53 mutated samples showed some response to cobimetinib, Nine AML samples were sensitive to cobimetinib with less than 80% viability after 24 h treatment with 50 nM of the compound, of which six were FLT3wt, one FLT3-ITD and two TP53 mutated AML.